Myovant Sciences Ltd. MYOV
Set alert
26.98 +26.98 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 2.62B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -26.19
- Beta
- 2.15
- Short ratio
- 11.21
- Inst. own
- 56.21%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 26, 2023
- 50-d avg
- 26.92
- 200-d avg
- 21.54
- 1y target
- 27.00
Analyst view
Consensus: hold
Hold
Price target (mean) 27.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy2
- Buy4
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 4
- 2 months ago 4
- 3 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.51 | -0.67 – -0.36 | -0.63 | +19.0% | 105.76M | +83.7% | 4 |
| Next quarter | -0.27 | -0.57 – 0.21 | -0.22 | -22.7% | 123.78M | +6.3% | 3 |
| Current year | -1.69 | -2.00 – -1.49 | -2.22 | +23.9% | 419.54M | +81.6% | 4 |
| Next year | -1.03 | -1.80 – 0.48 | -1.69 | +39.1% | 545.17M | +29.9% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 26, 2022 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| Oct 25, 2022 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Oct 24, 2022 | Baird | Downgrade | Outperform | Neutral |
| Aug 9, 2022 | SVB Leerink | Upgrade | Market Perform | Outperform |
| Jul 28, 2022 | Goldman Sachs | Maintained | — | Neutral |
| May 11, 2022 | Goldman Sachs | Maintained | — | Neutral |
| Apr 13, 2022 | SVB Leerink | Maintained | — | Market Perform |
| Feb 16, 2022 | SVB Leerink | Maintained | — | Market Perform |
| Jan 5, 2022 | SVB Leerink | Maintained | — | Market Perform |
| Oct 27, 2021 | SVB Leerink | Maintained | — | Market Perform |
| Sep 9, 2021 | SVB Leerink | Initiated | — | Market Perform |
| Feb 12, 2021 | SVB Leerink | Maintained | — | Market Perform |
| Jan 8, 2021 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Jan 6, 2021 | Goldman Sachs | Downgrade | Buy | Neutral |
| Aug 12, 2020 | SVB Leerink | Maintained | — | Outperform |
| Jul 7, 2020 | SVB Leerink | Maintained | — | Outperform |
| Jun 2, 2020 | Citigroup | Maintained | — | Neutral |
| Jun 1, 2020 | JP Morgan | Maintained | — | Overweight |
| May 19, 2020 | SVB Leerink | Maintained | — | Outperform |
| Aug 28, 2019 | Goldman Sachs | Initiated | — | Buy |
| Aug 19, 2019 | SVB Leerink | Initiated | — | Outperform |
| Apr 12, 2019 | Evercore ISI Group | Initiated | — | Outperform |
| Feb 13, 2019 | Barclays | Upgrade | Equal-Weight | Overweight |
| Nov 19, 2018 | Citigroup | Maintained | Buy | Buy |
| Oct 26, 2018 | Goldman Sachs | Initiated | — | Neutral |
| Sep 13, 2018 | JP Morgan | Initiated | — | Overweight |
| Apr 5, 2018 | Barclays | Downgrade | Overweight | Equal-Weight |
| Aug 17, 2017 | Evercore ISI Group | Initiated | — | Outperform |
| Nov 21, 2016 | Cowen & Co. | Initiated | — | Outperform |
| Nov 21, 2016 | Baird | Initiated | — | Outperform |